What does OPSUMIT/OPSYNVI — sales to customers (note 9) mean?

This metric represents the total net revenue generated from the sale of specific pharmaceutical products within the pulmonary arterial hypertension portfolio. It reflects the market demand and commercial performance of these specialized therapeutic assets. Tracking this revenue stream is essential for evaluating the growth trajectory and competitive positioning of the company's core pharmaceutical segments.

Johnson & Johnson JNJ OPSUMIT/OPSYNVI — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY

$5.63B+7.0%

DARZALEX

$3.96B+22.5%

Other

$2.9B+2.1%

SPINE,SPORTS & OTHER

$2.85B-2.5%

Tremfya

$1.61B+68.2%

GENERAL

$1.39B+4.9%

ADVANCED

$1.12B+4.7%

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA

$1.04B+15.0%

CONTACT LENSES / OTHER

$969M+5.4%

ERLEADA

$949M+23.1%

TRAUMA

$833M+7.9%

SPINE & OTHER

$694M+3.4%

IMBRUVICA

$660M-6.9%

STELARA

$656M-59.6%

SIMPONI / SIMPONI ARIA

$647M-1.8%

XARELTO

$642M-7.0%

CARVYKTI

$597M+61.8%

UPTRAVI

$483M+7.1%

SPRAVATO

$468M+46.3%

PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA

$443M+9.9%

HIPS

$436M+6.6%

Remicade

$422M-9.6%

KNEES

$420M+8.0%

EDURANT/rilpivirine

$409M+14.2%

other cardiovascular

$397M+4.5%

SURGICAL

$396M+9.7%

CAPLYTA

$270M—

OTHER NEUROSCIENCE

$262M-5.4%

RYBREVANT + LAZCLUZE

$257M+82.3%

Tecvayli

$202M+33.8%

Other Oncology

$192M-10.3%

TALVEY

$152M+76.7%

CONCERTA/Methylphenidate

$136M-8.1%

OTHER IMMUNOLOGY

$46M+4,500%

OTHER INFECTIOUS DISEASES

$37M-9.8%

Similar metrics at other companies

BMYOpdualag — Total Revenues

$295M+17.1%

BHCProduct sales — Revenue

$2.5B+12.3%

MIRMProduct sales, net — Product sales, net

$159.88M+43.3%

BMYOpdivo — Total Revenues

$2.15B-5.3%

TOISpecialty Pharmacy — Total operating revenue

$87.54M+77.6%

NAG

NAGEPharmaceuticals segment — Sales, net

$0—

Other financials

Income statement

See full

Revenue$24.1B+9.9%

Gross profit$16.0B+9.8%

Operating income$6.3B+2.3%

Net income$5.2B-52.4%

EPS (diluted)$2.14-52.9%

Balance sheet

See full

Cash & equivalents$21.7B-43.6%

Total debt$55.0B+5.2%

Total equity$81.2B+3.9%

Total assets$200.89B+3.7%

Cash flow

See full

Operating cash flow$2.5B-39.8%

CapEx$1.0B+31.9%

Free cash flow$1.5B-56.6%

Valuation

See full

Market cap$623.71B+66.9%

Enterprise value$657.01B+61.9%

P/E29.6×+13.2×

P/S6.5×+2.3×

Profitability

See full

Gross margin67.8%-0.5pp

Operating margin26.4%+2.8pp

Net margin21.8%-2.6pp

FCF margin18.5%-4.3pp

Returns & leverage

See full

Return on equity26.4%-3.0pp

Debt / equity0.7×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's opsumit/opsynvi — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Johnson & Johnson's OPSUMIT/OPSYNVI — sales to customers (note 9)?: Johnson & Johnson (JNJ) reported OPSUMIT/OPSYNVI — sales to customers (note 9) of $606M in Q1 2026.
How has Johnson & Johnson's OPSUMIT/OPSYNVI — sales to customers (note 9) changed year-over-year?: Johnson & Johnson's OPSUMIT/OPSYNVI — sales to customers (note 9) increased by 16.1% year-over-year, from $522M to $606M.
What does OPSUMIT/OPSYNVI — sales to customers (note 9) mean?: This metric represents the total net revenue generated from the sale of specific pharmaceutical products within the pulmonary arterial hypertension portfolio. It reflects the market demand and commercial performance of these specialized therapeutic assets. Tracking this revenue stream is essential for evaluating the growth trajectory and competitive positioning of the company's core pharmaceutical segments.